eli lilly oral glp-1 FDA approves new weight-loss pill, Foundayo The Bioinformatics Behind Eli Lilly's

Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB

To facilitate further understanding of its pathogenesis and exploring novel therapeutics, this review provides comprehensive information of ARDS from pathophysiology to molecular mechanisms and presents targeted therapeutics

Zhai, S., Liu, C., Vimalraj, S., Subramanian, R., Abullais, S

Medical Student Scholars for Health Equity in Myeloma at National Medical Association Annual Convention, New York, NY, 2024

Growing evidence suggests that numerous cancers, including hematopoietic tumors, may be driven by a small subset of cells known as tumor-initiating cells (TICs) [15]

Plaintiffs point to pre-approval clinical trials and post-marketing adverse event reports that accumulated evidence of severe gastrointestinal complications years before manufacturers updated warning labels to reflect these serious risks